Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

CompletedOBSERVATIONAL

Enrollment

13,309

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

May 26, 2023

Study Completion Date

May 26, 2023

Conditions

SARS-CoV-2

Trial Locations (1)

CMIC Co., Ltd., Tokyo

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY